DIVA Laboratories Ltd
DIVA Laboratories, Ltd. engages in the development, manufacture, and sale of medical equipment and computer related devices worldwide. The company provides endo/surgical displays, a static and dynamic image for hybrid and integrated ORs applications; color and mono displays for radiology and medical imaging applications; touch displays/human machine interface products; medical and industrial case… Read more
DIVA Laboratories Ltd (4153) - Total Liabilities
Latest total liabilities as of June 2025: NT$422.17 Million TWD
Based on the latest financial reports, DIVA Laboratories Ltd (4153) has total liabilities worth NT$422.17 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
DIVA Laboratories Ltd - Total Liabilities Trend (2017–2024)
This chart illustrates how DIVA Laboratories Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
DIVA Laboratories Ltd Competitors by Total Liabilities
The table below lists competitors of DIVA Laboratories Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CPE Technology Berhad
KLSE:5317
|
Malaysia | RM23.34 Million |
|
Negri Sembilan Oil Palms Bhd
KLSE:2038
|
Malaysia | RM226.13 Million |
|
Focus Lighting and Fixtures Limited
NSE:FOCUS
|
India | ₹656.70 Million |
|
Noodles & Company
NASDAQ:NDLS
|
USA | $319.47 Million |
|
Bangkok Ranch PCL
BK:BR
|
Thailand | ฿5.26 Billion |
|
Byggmästare Anders J Ahlström Holding AB (publ)
ST:AJA-B
|
Sweden | Skr8.02 Million |
|
Iofina plc
PINK:IOFNF
|
USA | $19.91 Million |
Liability Composition Analysis (2017–2024)
This chart breaks down DIVA Laboratories Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.43 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.30 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how DIVA Laboratories Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for DIVA Laboratories Ltd (2017–2024)
The table below shows the annual total liabilities of DIVA Laboratories Ltd from 2017 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$249.94 Million | +18.50% |
| 2023-12-31 | NT$210.93 Million | -10.48% |
| 2022-12-31 | NT$235.62 Million | +20.66% |
| 2021-12-31 | NT$195.27 Million | +57.05% |
| 2020-12-31 | NT$124.34 Million | -26.03% |
| 2019-12-31 | NT$168.09 Million | +21.05% |
| 2018-12-31 | NT$138.87 Million | -45.51% |
| 2017-12-31 | NT$254.84 Million | -- |